Therapeutic opportunities for targeted liposomal drug delivery

Advanced Drug Delivery Reviews

Volumn 21, Issue 2, 1996, Pages 117-133

  Allen, Theresa M ^a   Moase, Elaine H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antibody mediated targeting; anticancer drugs; ligand mediated targeting; long circulating liposomes; targeted drug delivery

Indexed keywords

ANTIBODIES; CELLS; ONCOLOGY; POLYETHYLENE GLYCOLS; TOXICITY;

ANTIBODY MEDIATED TARGETING; ANTICANCER DRUGS; CYTOTOXICITY; LIGAND MEDIATED TARGETING; LIPOSOMES; MICROMETASTATIC CELLS; TARGETED DRUG DELIVERY;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; AVIDIN; BIOTIN; CANCER ANTIBODY; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; POLYMER; RECEPTOR; VINCRISTINE;

BLOOD VESSEL; COVALENT BOND; CYTOTOXICITY; DRUG BINDING; DRUG TARGETING; HALF LIFE TIME; HUMAN; HYDROPHILICITY; INTERNALIZATION; METASTASIS; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0030590496     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00402-4     Document Type: Review

References (100)

1. [1] Sharma, A., Mayhew, E. and Straubinger, R.M. (1993) Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumour model. Cancer Res. 53, 5877-5881.
2. [2] Straubinger, R.M., Sharma, A., Murray, M. and Mayhew, E. (1993) Novel taxol formulations: taxol-containing liposomes. Monographs Natl. Cancer Inst. 15, 69-78.
3. [3] Sharma, A., Straubinger, R.M., Ojima, I. and Bernacki, R.J. (1995) Antitumor efficacy of taxane liposomes on a human ovarian tumour xenograft in nude athymic mice. J. Pharm. Sci. 84, 1400-1404.
4. [4] Scialli, A.R., Desesso, J.M., Rahman, A., Husain, S.R. and Goeringer, G.C. (1995) Embryotoxicity of free and liposome encapsulated taxol in the chick. Pharmacology 51, 145-151.
5. [5] Perez-Soler, R., Francis, K., al-Baker, S., Pilkiewicz, F. and Khokhar, A.R. (1994) Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. J. Microencapsulation 11, 41-54.
6. [6] Mori, A., Wu, S.P., Han, I., Khokhar, A.R., Perez-Soler, R. and Huang, L. (1996) In vivo antitumor activity of cis-bis-neodecanoato-trans-R.R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother. Pharmacol. 37, 435-444.
7. [7] Mayhew, E., Papahadjopoulos, D., Rustum, Y.M. and Dave, C. (1976) Inhibition of tumour cell growth in vitro and in vivo by 1-ß-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. Cancer Res. 36, 4406-4411.
8. [8] Kim, S. and Howell, S.B. (1987) Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy. Cancer Treat. Rep. 71, 705-711.
9. [9] Hong, F. and Mayhew, E. (1989) Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine. Cancer Res. 49, 5097-5102.
10. [10] Allen, T.M., Mehra, T., Hansen, C. and Chin, Y.C. (1992) Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 52, 2431-2439.
11. [11] Gabizon, A.A., Shiota, R. and Papahadjopoulos, D. (1989) Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 81, 1484-1488.
12. [12] Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A. and Barenholz, Y. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987-992.
13. [13] Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F.M. and Gabizon, A. (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 13, 1777-1785.
14. [14] Goebel, F.-D., Goldstein, D., Goos, M., Jablonowski, H. and Stewart, J.S. (1996) Efficacy and safety of StealthR liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br. J. Cancer 73, 989-994.
15. [15] Northfelt, D.W., Martin, F.J., Working, P., Volberding, P.A., Russell, J., Newman, M., Amantea, M.A. and Kaplan, L.D. (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety inpatients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36, 55-63.
16. [16] Cowens, J.W., Creaven, P.J., Greco, W.R., Brenner, D.E., Tung, Y., Ostro, M., Pilkiewicz, F., Ginsberg, R. and Petrelli, N. (1993) Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 53, 2796-2802.
17. [17] Mayer, L.D., Gelmon, K., Cullis, P.R., Boman, N., Webb, M.S., Embree, L., Tolcher, T. and Bally, M.B. Preclinical and clinical studies with liposomal vincristine., In: Progress in Drug Delivery, Biomedical Research Foundation, Tokyo, 1995, pp. 151-161.
18. [18] Gill, P.S., Espina, B.M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J.A., Liebman, H.A., Forssen, E., Ross, M.E. and Levine, A.M. (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal doxorubicin. J. Clin. Oncol. 13, 996-1003.
19. [19] Allen, T.M., Newman, M.S., Woodle, M.C., Mayhew, E. and Uster, P.S. (1995) Pharmacokinetics and antitumour activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer 62, 199-204.
20. [20] Allen, T.M., Hansen, C.B. and Lopes De Menezes, D.E. (1995) Pharmacokinetics of long circulating liposomes. Adv. Drug Del. Rev. 16, 267-284.
21. [21] Embree, L., Gelmon, K.A., Tolcher, T., Heggie, J.R., Hudon, N.J., Dedhar, C., Bally, M.B. and Mayer, L.D. (1996) Clinical pharmacokinetics of vincristine sulphate liposome injection (VSLI). Proc. Am. Assoc. Cancer Res. 37, 179.
22. [22] Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S-K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C. and Martin, F.J. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88, 11 460-11 464.
23. [23] Gabizon, A.A. (1992) Selective tumour localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52, 891-896.
24. [24] Huang, S-K., Lee, K.D., Hong, K., Friend, D.S. and Papahadjopoulos, D. (1992) Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52, 5135-5143.
25. [25] Bakker-Woudenberg, I.A.J.M., Lokerse, A.F., ten Kate, M.T. and Storm, G. (1992) Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim. Biophys. Acta 1138, 318-326.
26. [26] Bakker-Woudenberg, I.A.J.M., Lokerse, A.F., ten Kate, M.T., Woodle, M.C. and Storm, G. (1993) Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumonia-infected lung tissue. J. Infect. Dis. 168, 164-171.
27. [27] Wu, N.Z., Da, D., Rudoll, T.L., Needham, D., Whorton, A.R. and Dewhirst, M.W. (1993) Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumour tissue. Cancer Res. 53, 3765-3770.
28. [28] Gabizon, A. and Papahadjopoulos, D. (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85, 6949-6953.
29. [29] Aragnol, D. and Lesserman, L. (1986) Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl. Acad. Sci. USA 83, 2699-2703.
30. [30] Rahman, A., Panneerselvam, M., Guirguis, R., Castronovo, V., Sobel, M.E., Abraham, K., Daddona, P.E. and Liotta, L.A. (1989) Anti-laminin receptor antibody targeting of liposomes with encapsulated doxorubicin to human breast cancer cells in vitro. J. Natl. Cancer Inst. 81, 1794-1800.
31. [31] Bankert, R.B., Yokota, S., Ghosh, S.K., Mayhew, E. and Jou, Y.H. (1989) Immunospecific targeting of cytosine arabinonucleoside-containing liposomes to the idiotype on the surface of a murine B-cell tumour in vitro and in vivo. Cancer Res. 49, 301-308.
32. [32] Ahmad, I. and Allen, T.M. (1992) Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 52, 4817-4820.
33. [33] Heath, T.D., Lopez, N.G., Piper, J.R., Montgomery. J.A., Stern, W.H. and Papahadjopoulos. D. (1986) Liposome-mediated delivery of pteridine antifolates to cells in vitro: potency of methotrexate, and its alpha and gamma substituents. Biochim. Biophys. Acta 862, 72-80.
34. [34] Moradpour, D., Compagnon, B., Wilson, B.E., Nicolau, C. and Wands, J.R. (1995) Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro. Hepatology 22, 1527-1537.
35. [35] Lee, R.J. and Low, P.S. (1995) Folate-mediated tumour cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233, 134-144.
36. [36] Debs, R.J., Heath, T.D. and Papahadjopoulos, D. (1987) Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration. Biochim. Biophys. Acta 901, 183-190.
37. [37] Matzku, S., Krempel, H., Weckenmann, H-P., Schirrmacher, V., Sinn, H. and Stricker, H. (1990) Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases. Cancer Immunol. Immunother. 31, 285-291.
38. [38] Allen, T.M., Agrawal, A.K., Ahmad, I., Hansen, C.B. and Zalipsky, S. (1994) Antibody-mediated targeting of long-circulating (Stealth®) liposomes. J. Liposome Res. 4, 1-25.
39. [39] Olson, F., Hunt, C.A., Szoka, F.C., Vail, W.J. and Papahadjopoulos, D. (1979) Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim. Biophys. Acta 557, 9-23.
40. [40] Mayer, L.D., Tai, L.C., Ko, D.S., Masin, D., Ginsberg, R.S., Cullis, P.R. and Bally, M.B. (1989) Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49, 5922-5930.
41. [41] Wu, N.Z., Da, D., Rudoll, T.I., Needham, D., Whorton, A.R. and Dewhirst, M.W. (1993) Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumour tissue. Cancer Res. 53, 3765-3770.
42. [42] Yuan, F, Leunig, M, Huang, S.K., Berk, D.A., Papahadjopoulos, D. and Jain, R.K. (1994) Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumour xenograft. Cancer Res. 54, 3352-3356.
43. [43] Huang, S.K., Martin, F.J., Friend, D.S. and Papahadjopoulos, D. Mechanism of Stealth liposome accumulation in some pathological tissues, In: Lasic, D. and Martin, F. (Eds.), Stealth Liposomes. CRC Press, Boca Raton, Fla, 1995, pp. 119-125.
44. [44] Mayer, L.D., Bally, M.B. and Cullis, P.R. (1986) Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 857, 123-126.
45. [45] Bolotin, E.M., Cohen, R., Bar, L.K., Emanuel, S.N., Lasic, D.D. and Barenholz, Y. (1994) Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J. Liposome Res. 4, 455-479.
46. [46] Boman, N.L., Mayer, L.D. and Cullis, P.R. (1993) Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta 1152, 253-258.
47. [47] Gabizon, A., Shiota, R. and Papahadjopoulos, D. (1989) Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 81, 1484-1488.
48. [48] Blume, G. and Cevc, G. (1990) Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1029, 91-97.
49. [49] Klibanov, A.L., Maruyama, K., Torchilin, V.P. and Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235-237.
50. [50] Senior, J., Delgado, C., Fisher, D., Tilcock, C. and Gregoriadis, G. (1991) Influence of surface hydrophobicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1062, 77-82.
51. [51] Allen, T.M., Hansen, C., Martin, F., Redemann, C. and Yau-Young, A. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066, 29-36.
52. [52] Allen, T.M. (1994) The use of glycolipids and hydrophillic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv. Drug Del. Rev. 13, 285-309.
53. [53] Parr, M.J., Ansell, S.M., Choi, L.S. and Cullis, P.R. (1994) Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta 1195, 21-30.
54. [54] Allen, T.M. and Hansen, C. (1991) Pharmacokinetics of Stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1068, 133-141.
55. [55] Hansen, C.B., Kao, G.Y., Moase, E.H., Zalipsky, S. and Allen, T.M. (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239, 133-144.
56. [56] Mori, A., Klibanov, A.L., Torchilin, V.P. and Huang, L. (1991) Influence of the steric barrier of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 284, 263-266.
57. [57] Maruyama, K., Yuda, T., Okamoto, A., Ishikura, C., Kojima, S. and Iwatsura, M. (1991) Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. Chem. Pharm. Bull. 39, 1620-1622.
58. [58] Klibanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P. and Huang, L. (1991) Activity of amphipathic poly(ethyleneglycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1062, 142-148.
59. [59] Lesserman, L.D., Barbet, J., Kourilsky, F. and Weinstein, J.N. (1980) Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288, 602-604.
60. [60] Martin, F.J., Hubbell, W.L. and Papahadjopoulos, D. (1981) Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. Biochemistry 20, 4229-4238.
61. [61] Martin, F.J. and Papahadjopoulos, D. (1982) Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem. 257, 286-288.
62. [62] Chua, M-M., Fan, S-T. and Karush, F. (1984) Attachment of immunoglobulin to liposomal membrane via protein carbohydrate. Biochim. Biophys. Acta 800, 291-300.
63. [63] Loughrey, H, Bally, M.B. and Cullis, P.R. (1987) A non-covalent method of attaching antibodies to liposomes. Biochim. Biophys. Acta 901, 157-160.
64. [64] Bogdanov, A.A., Klibanov, A.L. and Torchilin, V.P. (1988) Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N-hydorosulfosuccinimide. FEBS Lett. 231, 381-384.
65. [65] Holmberg, E., Maruyama, K., Litzinger, D.C., Wright, S., Davis, M., Kabalka, G.W., Kennel, S.J. and Huang, L. (1989) Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions. Biochem. Biophys. Res. Commun. 165, 1272-1278.
66. [66] Weiner, A.L. Chemistry and biology of immunotargeted liposomes. In: Tyle, P. and Ram, B.P. (Eds.), Targeted therapeutic systems. Marcel Dekker, Inc., New York, 1990, pp. 305-336.
67. [67] Torchilin, V.P. and Klibanov, A.L. (1993) Coupling of ligands with liposomes membrane. Drug Target. Del. 2, 227-238.
68. [68] Loughrey, H.C., Choi, L.S., Cullis. P.R. and Bally, M.B. (1990) Optimized procedures for the coupling of proteins to liposomes. J. Immunol. Meth. 132, 25-35.
69. [69] Harasym, T.O., Tardi, P., Longman, S.A., Ansell, S.M., Bally, M.B., Cullis, P.R. and Choi, L.S. (1995) Poly-(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjugate Chem. 6, 187-194.
70. [70] Zalipsky, S., Brandeis, E., Newman, M. and Woodle, M.C. (1994) Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett. 353, 71-74.
71. [71] Zalipsky, S., Chang, J.L., Albericio, F. and Barany, G. (1994) Preparation and applications of polyethylene glyol-polystyrene graft resin supports of solid phase peptide synthesis. Reactive Polymers 22, 243-258.
72. [72] Allen, T.M., Brandeis, E., Hansen, C.B., Kao, G.Y. and Zalipsky, S. (1995) A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237, 99-108.
73. [73] Zalipsky, S. (1995) Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjugate Chem. 6, 150-165.
74. [74] Kirpotin, D., Park, J.W., Hong, K., Keller, G., Benz, J. and Papahadjopoulos, D. (1996) Binding and endocytosis of sterically stabilized anti-HER2 immunoliposomes by human breast cancer cells. Proc. Am. Assoc. Cancer Res. 37, 467.
75. [75] Zalipsky, S. (1993) Synthesis of end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjugate Chem. 4, 296-299.
76. [76] Blume, G., Cevc, G., Crommelin, M.D., Bakker-Woudenberg, I.A., Kluft, C. and Storm, G. (1993) Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta 1149, 180-184.
77. [77] Klibanov, A.L. and Huang, L. (1992) Long-circulating liposomes: development and perspectives. J. Liposome Res. 2, 321-334.
78. [78] Maruyama, K., Kennel, S.J. and Huang, L. (1990) Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc. Natl. Acad. Sci. USA 87, 5744-5748.
79. [79] Suzuki, S., Watanabe, S., Masuko, T. and Hashimoto, Y. (1995) Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol). Biochim. Biophys. Acta 124, 9-16.
80. [80] Ohta, S., Igarashi, S., Honda, A., Sato, S. and Hanai, N. (1993) Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. Anticancer Res. 13, 331-336.
81. [81] Osdol, W.V., Fujimori, K. and Weinstein, J.N. (1991) An analysis of monoclonal antibody distribution in microscope tumour nodules: consequences of a 'binding site barrier'. Cancer Res. 51, 4776-4784.
82. HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 92, 1327-1331.
83. [83] Lopes de Menezes, D.E., Pilarski, L.M. and Allen, T.M. (1995) Selective cytotoxicity of immunoliposomal to B lymphocytes. Proc. Am. Assoc. Cancer Res. 35, 307.
84. [84] Mori, A., Kennel, S.I., Waalkes, M.V.B., Scherphof, G.L. and Huang, L. (1995) Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung metastasis model. Cancer Chemother. Pharmacol. 35, 447-456.
85. [85] Bloemen, P.G.M., Henricks, P.A.J., van Bloois, L., van den Tweel, M.C., Bloem, A.C., Nijkamp, F.P., Crommelin, D.J.A. and Storm, G. (1995) Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett. 357, 140-144.
86. [86] Nassander, U.K., Steerenberg, P.A., De Jong, W.H., Van Overveld, W.O.M., Te Boekhorst, C.M.E., Poels, L.G., Jap, P.H.K. and Storm, G. (1995) Design of immunoliposomes directed against human ovarian carcinoma. Biochim. Biophys. Acta 1235, 126-139.
87. [87] Maruyama, K., Takizawa, T., Yuda, T., Kennel, S.J., Huang, L. and Iwatsuru, M. (1995) Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta 1234, 74-80.
88. [88] Vingerhoeds, M.H., Haisma, H.J., Belliot, S.O., Smit, R.H.P., Crommelin, D.J.A. and Storm, G. (1996) Immunoliposomes as enzyme carriers (immuno enzymosomes) for antibody directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharmaceut. Res. 13, 604-610.
89. [89] Khaw, B-A., Torchilin, V.P., Vural, I. and Narula, J. (1995) Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosinliposomes. Nature Med. 1, 1195-1198.
90. [90] Yanagie, H., Tomita, T., Kobayashi, H., Fujii, Y., Takahashi, T., Hasumi, K., Nariuchi, H. and Sekiguchi, M. (1991) Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model. Brit. J. Cancer 63, 522-526.
91. [91] Briscoe, P., Caniggia, I., Graves, A., Benson, B., Huang, L., Tanswell, A.K. and Freeman, B.A. (1995) Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am. Physiol. Soc. 268, L374-L380.
92. [92] Daleke, D.L., Hong, K. and Papahadjopoulos, D. (1990) Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim. Biophys. Acta 1024, 352-366.
93. [93] Lundberg, B., Hong, K. and Papahadjopoulos, D. (1993) Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. Biochim. Biophys. Acta 1149, 305-312.
94. [94] Allen, T.M., Ahmad, I., Lopes de Menezes, D.E. and Moase, E.H. (1995) Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans. 23, 1073-1079.
95. [95] Marjan, J., Charrois, G., Lopes de Menezes, D.E. and Allen, T.M. (1996) Antibody-mediated targeting of liposomal doxorubicin to lymphoblastic cells can reverse multidrug resistance. Proc. Am. Assoc. Cancer Res. 37, 309.
96. [96] Ahmad, I., Longenecker, M., Samuel, J. and Allen, T.M. (1993) Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53, 1484-1488.
97. [97] Phillips, N.C. and Emili, A. (1991) Immunogenicity of immunoliposomes. Immunol. Lett. 30, 291-296.
98. + Leucocytes is dependent on immune status. J. Immunol. 152, 3168-3174.
99. [99] Torchilin, V.R. Klibanov, A.L., Huang, L., O'Donnell, S., Nossiff, N.D. and Khaw, B.A. (1992) Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 6, 2716-2719.
100. [100] Vingerhoeds, M.H., Steerenherg, P.A., Hendirks, J.J.G.W., Dekker, L.C., van Hoesel, Q.G.C.M., Crommelin, D.J.A. and Storm, G. (1996) Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Brit. J. Cancer (in press).